Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpiCord for Diabetic Foot Ulcers
NCT02844660Completed
- Sponsor
- MIMEDX
- Start
- Jul 2016
- Primary completion
- Jul 2018
- Modality
- Tissue Cells, Hydrogel Systems
- Countries
- 1
01
Overview
Randomised, open-label trial in diabetic foot ulcer (DFU) comparing EpiCord with Standard of Care (2 arms). Primary endpoints: Complete Ulcer Closure at 12 weeks and Study Safety Measurement at 12 weeks. Started Jul 2016; status: completed.
02
Drugs
human amniotic membrane allograft
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02844660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844660.